DE69834951D1 - Eine familie von genen mit transformationsmodulierender aktivität - Google Patents

Eine familie von genen mit transformationsmodulierender aktivität

Info

Publication number
DE69834951D1
DE69834951D1 DE69834951T DE69834951T DE69834951D1 DE 69834951 D1 DE69834951 D1 DE 69834951D1 DE 69834951 T DE69834951 T DE 69834951T DE 69834951 T DE69834951 T DE 69834951T DE 69834951 D1 DE69834951 D1 DE 69834951D1
Authority
DE
Germany
Prior art keywords
normal
cancer
transformation
prostate
sequence changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834951T
Other languages
English (en)
Other versions
DE69834951T2 (de
Inventor
R Pasternack
J Kocheavar
R Brody
S Kadkol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE69834951D1 publication Critical patent/DE69834951D1/de
Application granted granted Critical
Publication of DE69834951T2 publication Critical patent/DE69834951T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
DE69834951T 1997-12-12 1998-12-11 Eine familie von genen mit transformationsmodulierender aktivität Expired - Fee Related DE69834951T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6967797P 1997-12-12 1997-12-12
US69677P 1997-12-12
PCT/US1998/026433 WO1999029906A2 (en) 1997-12-12 1998-12-11 Gene family with transformation modulating activity

Publications (2)

Publication Number Publication Date
DE69834951D1 true DE69834951D1 (de) 2006-07-27
DE69834951T2 DE69834951T2 (de) 2007-02-08

Family

ID=22090529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834951T Expired - Fee Related DE69834951T2 (de) 1997-12-12 1998-12-11 Eine familie von genen mit transformationsmodulierender aktivität

Country Status (7)

Country Link
EP (1) EP1045926B1 (de)
JP (1) JP2002508154A (de)
AT (1) ATE330030T1 (de)
AU (1) AU1724699A (de)
CA (1) CA2311645A1 (de)
DE (1) DE69834951T2 (de)
WO (1) WO1999029906A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930175B1 (en) 1997-12-12 2005-08-16 The Johns Hopkins University School Of Medicine Gene family with transformation modulating activity
EP1146909A4 (de) * 1999-02-03 2004-12-29 Univ Johns Hopkins Verfahren zur behandlung von krebs mittels wiederherstellung der pp32-funktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734022A (en) * 1990-08-01 1998-03-31 The Johns Hopkins University Antibodies to a novel mammalian protein associated with uncontrolled cell division
GB9216851D0 (en) * 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene

Also Published As

Publication number Publication date
EP1045926B1 (de) 2006-06-14
EP1045926A2 (de) 2000-10-25
WO1999029906A3 (en) 1999-08-26
DE69834951T2 (de) 2007-02-08
CA2311645A1 (en) 1999-06-17
JP2002508154A (ja) 2002-03-19
ATE330030T1 (de) 2006-07-15
AU1724699A (en) 1999-06-28
WO1999029906A2 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
Papp et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
EP1272636B8 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
ATE241375T1 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
Miyake et al. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MX9708401A (es) Genes reguladores de la cromatina.
EP1455840A4 (de) Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha
HK1033910A1 (en) Use of erythropoietin in the treatment of multiple myeloma
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
DE69834951D1 (de) Eine familie von genen mit transformationsmodulierender aktivität
BR9707994A (pt) Adenovírus recombinantes defectivo composição farmacêutica utilização do adenovirus composição e processo de preparação de células t citotóxicas especificas de um antigene tumoral
MX9606559A (es) Terapia para el cancer usando linfotoxina.
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
TR200101141T2 (tr) Antitümör etkiyi haiz antijenik proteini şifreleyen bir DNA'ya mahsus parçalar ihtiva eden farmasötik bileşim
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
WO2001072341A3 (en) Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
HK1118861A1 (en) Genes differentially expressed in breast cancer
EP1351967A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2002045657A3 (en) Ovarian tumor antigen and methods of use therefor
WO2001021653A3 (en) Ovarian tumor antigen and methods of use therefor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee